Business Wire

XPENG

10.3.2022 14:02:20 CET | Business Wire | Press release

Share
XPENG kicks off P5 smart EV sedan reservation in four European markets and opens XPENG Experience Store in the Netherlands

XPENG (the “Company”, NYSE: XPEV and HKEX: 9868), a leading smart mobility and technology company, today kicks off customer reservations of its third and latest production model on the market, the XPENG P5 smart EV sedan, simultaneously in Denmark, the Netherlands, Norway and Sweden. The move marks a major milestone in its European expansion plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005596/en/

XPENG today is also opening its first XPENG Experience Store in the Netherlands, its second branded showroom in Europe, following the opening of the Stockholm XPENG Experience Store in Sweden last month.

The XPENG P5 is the Company’s first model to be made available simultaneously in four European markets. The customer reservation process is fully-digitized, and accessible immediately in each of these four markets, both via the XPENG official websites in each country, and the XPENG mobile APP launched earlier this week.

“The XPENG P5’s arrival in four key European markets is a new demonstration of our commitment to Europe,” said Leon He, Vice President of XPENG. “Each new XPENG model achieves a new level of technology sophistication. The P5 brings a host of differentiated features to a new customer base in Europe, a market where we are building ourselves as a long-term player,” said Mr. He.

The XPENG P5 – Intelligence that moves you

The XPENG P5, a mid-size family sedan, is equipped with version 2.5 of XPENG’s in-house developed Advanced Driver Assistance System (XPILOT), and its intelligent in-car operating system - Xmart OS. The P5 combines the advanced level of driver assistance with superior passenger comfort and convenience. Through firmware over-the-air (OTA) upgrades, the P5 will bring new features and optimized functions to customers on a continuous basis.

The sleek aerodynamic profile of the P5 with a large panoramic canopy glass sunroof, neat fastback and unobtrusive ducktail gives it a driving range of 465 km WLTP, powered by a battery of 66 kWh capacity.

The Xmart OS provides comprehensive cockpit and interior function management, with a 12.3-inch LCD dashboard, a 15.6-inch FHD high resolution (1920 * 1080) large center display, in-car voice control capable of distinguishing between driver and passenger positions, and a library of in-car Apps to assist, inform, and entertain driver and passengers.

This intelligent cockpit management is integrated into the stylish interior fittings, with heated leatherette seats, the Xfreebreath intelligent air purification system and advanced surround sound system. Many vehicle functions can also be accessed via mobile phone remote control.

For added convenience, the P5 incorporates 26 storage compartments and a 450L large trunk, plus an additional 70L compartment underneath.

XPENG experience store starts operation in the Netherlands

Concurrently, XPENG is also opening its first experience store in the Westfield Mall of the Netherlands in Leidschendam, conveniently close to major conurbations such as Rotterdam and The Hague. As well as the XPENG P5, the XPENG smart sports sedan P7, and the prototype of its flying vehicle XPENG X2 are also on display in the Westfield Mall experience store, demonstrating the brand’s vision of future mobility and its spirit of exploration.

Customers can make online reservations for XPENG P5 from today. The test drive will be available in April 2022.

Two additional stores in the Netherlands will open later this year in collaboration with XPENG's local partner Emil Frey, and the Company plans to open more stores in major cities across the Netherlands over the next few years.

XPENG P5 Specs

Dimension

Length x Width x Height (mm)

4808mm / 1840mm / 1520mm

Wheelbase (mm)

2768mm

Seats

5

Curb Weight (kg)

1715Kg

Cargo Space

520 L

 

Performance

Type of Drive

Front-wheel drive

Battery Capacity (kWh)

66 kWh

WLTP Driving Range (km)

465 Km

 

XPILOT 2.5 (ADAS)

High-definition Millimeter Wave Radar

5

Ultrasonic Wave Sensors

12

Autonomous Driving Surround View Camera

4

Autonomous Driving High Perception Camera

9

XPILOT Safety

XPILOT Driving

XPILOT Parking

 

Xmart OS In-car Intelligent System

15.6" Central Touch Screen Display

12.3" HD Liquid Crystal Intelligent Instrument Panel

Mobile App Remote Control

"Hey XPENG" Voice Assistant

Firmware over-the-air software updates

 

Exterior

Lightsaber 3.0 LED Lights

Lightsaber 3.0 LED DRL

Panoramic Sunroof

215/55R18 Michelin Tyre

 

About XPENG

XPENG is a leading smart mobility company founded with a mission to explore and drive smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley and San Diego. In 2021, XPENG established its European headquarters in the Netherlands, and is expanding its presence in Sweden, Norway and Denmark. XPENG's smart EVs are manufactured at its fully-owned plant in Zhaoqing, Guangdong Province, China. For more information, please visit: www.heyxpeng.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye